Financial results to be released after market close; Conference call...
Read More
Menu
Investor Updates
NASDAQ: INVO
Our mission is to increase worldwide access to advanced reproductive treatment. Our revolutionary technology, INVOcell, allows incubation to take place within the woman’s body. The lab and clinical efficiencies created by INVOcell increase capacity and reduce cost thus opening the door for more people to receive treatment. Our unique go-to-market approach includes clinicians who are expanding their fertility options, INVO Centers and IVF practices.
Stock Info
Quaterly Reports
SEC Fillings
Stock Info
Detailed Stock Quote
Stock Charts
Historical Quotes
Quaterly Reports
Balance Sheet
Income Statement
Cash Flow
Related Documents
SEC Fillings
Press Releases
INVO Reports Fourth Quarter and Full Year 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA,...
Read MoreINVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023
Financial results to be released after market close; Conference call...
Read MoreCompany Contact
Investor Contact
We're scaling globally
Full-service solution: Revolutionary technology combined with training, lab services and business support
Increase geographic availability and reduce cost to patients: Our simple procedure has limited infrastructure costs, allowing more clinicians to include INVOcell in their practices away from large metro areas. And in markets where there is significant out of pocket costs, they can pass those savings on to their patients.
Innovative Go-to-market strategy: By building INVOcell-only clinics, partnering with distributors, and offering INVOcell in current IVF clinics, OB/GYN offices and women’s health clinics we will gain market share, and disrupt the infertility space.
Our people: We are a team of smart, aggressive people backed by a strong board of directors, strategic consultants, & key partners.
